Literature DB >> 17590247

Plasminogen activator system in oral squamous cell carcinoma.

E A Baker1, D J Leaper, J P Hayter, A J Dickenson.   

Abstract

BACKGROUND: The plasminogen activator system consists of two plasminogen activators, urokinase (uPA) and tissue (tPA); PA inhibitors (PAI-1, and -2), and a cell surface receptor for uPA (uPAR). The plasminogen activator system is involved at many stages of the metastatic cascade, including matrix remodelling, cell proliferation, and migration. AIMS: To compare tissue concentrations of the components of the plasminogen activator system in paired tumour tissue and normal tissue in patients with oral squamous cell carcinoma, and to correlate these with the histopathological grading of the tumour.
METHODS: Thirty-eight paired tissue samples were analysed by enzyme-linked immunosorbent assays (ELISA; ng/mg protein) for uPA, tPA, uPAR, PAI-1, and PAI-2.
RESULTS: Concentrations of uPA, uPAR, PAI-1, and PAI-2 were significantly higher in tumour than in normal oral tissue (median in uPAR tumour 1.6 (range; 0.1-7.5) ng/mg protein; normal=0.2 (0-2.3), p<0.05). There were strong correlations between the concentrations of certain components of the plasminogen activator system in particular between uPA, uPAR, and PAI-1 (p<0.05). Tissue concentrations of some components of the plasminogen activator system correlated with clinical and pathological indexes of aggression of tumours, including differentiation and T-stage.
CONCLUSION: The relation between components of the plasminogen activator system, in particular uPA, uPAR, and PAI-1 in invasion, metastasis, prognosis, and survival, requires further investigation in oral squamous cell carcinomas.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17590247     DOI: 10.1016/j.bjoms.2007.04.021

Source DB:  PubMed          Journal:  Br J Oral Maxillofac Surg        ISSN: 0266-4356            Impact factor:   1.651


  10 in total

1.  Porphyromonas gingivalis promotes invasion of oral squamous cell carcinoma through induction of proMMP9 and its activation.

Authors:  Hiroaki Inaba; Hideyuki Sugita; Masae Kuboniwa; Soichi Iwai; Masakazu Hamada; Takeshi Noda; Ichijiro Morisaki; Richard J Lamont; Atsuo Amano
Journal:  Cell Microbiol       Date:  2013-09-19       Impact factor: 3.715

2.  Gene Expression Signatures of Lymph Node Metastasis in Oral Cancer: Molecular Characteristics and Clinical Significances.

Authors:  Xiqiang Liu; Antonia Kolokythas; Jianguang Wang; Hongzhang Huang; Xiaofeng Zhou
Journal:  Curr Cancer Ther Rev       Date:  2010-11-01

3.  Prognostic value analysis of urokinase-type plasminogen activator receptor in oral squamous cell carcinoma: an immunohistochemical study.

Authors:  Roberta Bacchiocchi; Corrado Rubini; Elisa Pierpaoli; Giulia Borghetti; Pasquale Procacci; Pier Francesco Nocini; Andrea Santarelli; Romina Rocchetti; Domenico Ciavarella; Lorenzo Lo Muzio; Francesca Fazioli
Journal:  BMC Cancer       Date:  2008-08-01       Impact factor: 4.430

4.  SERPINE1 and SMA expression at the invasive front predict extracapsular spread and survival in oral squamous cell carcinoma.

Authors:  J Dhanda; A Triantafyllou; T Liloglou; H Kalirai; B Lloyd; R Hanlon; R J Shaw; D R Sibson; J M Risk
Journal:  Br J Cancer       Date:  2014-09-30       Impact factor: 7.640

5.  Pericyte FAK negatively regulates Gas6/Axl signalling to suppress tumour angiogenesis and tumour growth.

Authors:  Tanguy Lechertier; Louise E Reynolds; Hyojin Kim; Ana Rita Pedrosa; Jesús Gómez-Escudero; José M Muñoz-Félix; Silvia Batista; Matthew Dukinfield; Fevzi Demircioglu; Ping Pui Wong; Kylie P Matchett; Neil C Henderson; Gabriela D'Amico; Maddy Parsons; Catherine Harwood; Pascal Meier; Kairbaan M Hodivala-Dilke
Journal:  Nat Commun       Date:  2020-06-04       Impact factor: 14.919

6.  Deregulation of extracellular matrix modeling with molecular prognostic markers revealed by transcriptome sequencing and validations in Oral Tongue squamous cell carcinoma.

Authors:  Soundara Viveka Thangaraj; Vidyarani Shyamsundar; Arvind Krishnamurthy; Vijayalakshmi Ramshankar
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

Review 7.  Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer.

Authors:  Bing-Tao Zhai; Huan Tian; Jing Sun; Jun-Bo Zou; Xiao-Fei Zhang; Jiang-Xue Cheng; Ya-Jun Shi; Yu Fan; Dong-Yan Guo
Journal:  J Transl Med       Date:  2022-03-18       Impact factor: 5.531

8.  Urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1) are potential predictive biomarkers in early stage oral squamous cell carcinomas (OSCC).

Authors:  Synnøve Magnussen; Oddveig G Rikardsen; Elin Hadler-Olsen; Lars Uhlin-Hansen; Sonja E Steigen; Gunbjørg Svineng
Journal:  PLoS One       Date:  2014-07-07       Impact factor: 3.240

Review 9.  Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.

Authors:  Niaz Mahmood; Catalin Mihalcioiu; Shafaat A Rabbani
Journal:  Front Oncol       Date:  2018-02-12       Impact factor: 6.244

Review 10.  uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.

Authors:  Miguel Angel Pavón; Irene Arroyo-Solera; Maria Virtudes Céspedes; Isolda Casanova; Xavier León; Ramón Mangues
Journal:  Oncotarget       Date:  2016-08-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.